Aldara is owned by Bausch.
Aldara contains Imiquimod.
Aldara has a total of 2 drug patents out of which 0 drug patents have expired.
Aldara was authorised for market use on 27 February, 1997.
Aldara is available in cream;topical dosage forms.
Aldara can be used as treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); works through the induction of interferon and other cytokines.
The generics of Aldara are possible to be released after 01 October, 2024.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7696159||BAUSCH||Treatment for basal cell carcinoma|| |
(1 year, 10 days from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|BAUSCH||Treatment for basal cell carcinoma|| |
(1 year, 6 months from now)
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 27 February, 1997
Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic